Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.
The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Using this cis-activation strategy in primary cells and muscle, we have demonstrated an increase in transgene expression of more than 600-fold from a minimal simian virus 40 (SV40) promoter and an ...
The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...
WHO and the Uganda Health Ministry have launched a first-ever vaccine trial for the species of Ebola at the center of an ...
In a global first, Uganda’s Ministry of Health, the World Health Organization, and other partners launched a first-ever ...
The Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 786.7 Bn in 2023, growing at a CAGR of 5.8% As scientific and technological advancements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback